All In Biotech

Drug Trial Radar · NCT07735533

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

274

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2031

Study completion Aug 2031

Sponsor

Lead sponsor
Umoja BiopharmaIndustry
Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).

Conditions

  • Lymphoma, B Cell
  • Lymphoma Non-Hodgkin
  • High Grade B Cell Lymphoma
  • Richter Transformation Lymphoma
  • Grade 3b Follicular Lymphoma
  • Primary Mediastinal B Cell Lymphoma
  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

  • UB-VV400Genetic

    UB-VV400 is a gene therapy that generates CD22-directed CAR T cells in the body.

  • Rapamycin (sirolimus)Drug

    Rapamycin is a drug approved by the FDA for indications unrelated to cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of participants with common adverse events (AEs)Time frame: Up to 2 years after UB-VV400 administration
  2. Phase 2: Overall response rate (ORR)Time frame: Up to 2 years after UB-VV4001 administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Irvine, California · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.